Research programme: small molecule therapeutics - e-Therapeutics

Drug Profile

Research programme: small molecule therapeutics - e-Therapeutics

Alternative Names: ETS 2123; ETS 5200; ETS 6114; ETS 7211; ETS2300; ETS2400; ETS6200; ETX 6201; ETX 6765

Latest Information Update: 28 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator e-Therapeutics
  • Class Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Viral infections
  • Research Fibrosis
  • No development reported Cancer; Neurodegenerative disorders
  • Discontinued Age-related macular degeneration; Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in United Kingdom
  • 22 Mar 2016 Preclinical trials in Viral infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top